Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.

@article{Dignass2012SecondEE,
  title={Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.},
  author={Axel U Dignass and James O. Lindsay and Andreas Sturm and Alastair Windsor and J F Colombel and Mathieu Allez and Geert R D'Haens and Andre D'hoore and Gerassimos J Mantzaris and Gottfried Novacek and Tom Oresland and Walter Reinisch and Miquel Sans and Eduard F Stange and S{\'e}verine Vermeire and Simon P L Travis and Gert Van Assche},
  journal={Journal of Crohn's \& colitis},
  year={2012},
  volume={6 10},
  pages={
          991-1030
        }
}
Inducing remission of ulcerative colitis: are clinicians better equipped than ever?
TLDR
A new definition of ‘deep remission’, including clinical, endoscopic and histological findings, should be considered as the therapeutic goal of ulcerative colitis patients, and the efficacy and safety of mesalazine (5-ASA) in inducing and maintaining clinical remission in mild-to-moderate UC is confirmed.
Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.
TLDR
Canadian consensus guidelines for the treatment of ambulatory patients with mild to severe active UC conclude that the goal of therapy is complete remission, defined as both symptomatic and endoscopic remission without corticosteroid therapy.
Ulcerative proctitis: an update on the pharmacotherapy and management
TLDR
Topically administered 5-aminosalicylates (5-ASA) and corticosteroids are effective in the treatment of proctitis, although they seem to be underused in everyday practice.
Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies
TLDR
The overall risk of CRC and mortality was not significantly different from that of the background population, and patients with distal disease who progress to extensive colitis seem to be a subgroup with an especially high risk of colectomy.
[Second Korean Guideline for the Management of Ulcerative Colitis].
  • C. Choi, W. Moon, D. Han
  • Medicine
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • 2017
TLDR
This guideline encompasses treatment of active colitis, maintenance of remission, and indication of surgery for UC, and was generally made by the adaptation of several foreign guidelines as was the first edition.
Concise Commentary: Second Line Is Not Second Best—Continuing Validity of the Oxford Criteria in the Management of Acute Severe Ulcerative Colitis
TLDR
The study by Moore and Bressler confirms that the Oxford criteria are still relevant to the modern management of ASUC and shows that when these criteria are used in real-life conditions, the risk of colectomy is one-third during hospital admission and 45% in the first 90 days.
Second Korean guidelines for the management of ulcerative colitis
TLDR
This is an update of the first Korean guidelines for the management of UC, and encompasses treatment of active colitis, maintenance of remission, and indication of surgery for UC.
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy.
TLDR
Optimal management of IBD before and during pregnancy is essential to achieving favorable maternal and neonatal outcomes.
...
...

References

SHOWING 1-10 OF 485 REFERENCES
The pattern and outcome of acute severe colitis.
Predicting outcome in severe ulcerative colitis.
TLDR
If the early pattern of change in inflammatory markers or other variables could predict the need for surgery and the outcome of medical treatment during one year follow up is evaluated, patients with frequent stools, or raised CRP, need to be identified, as most will require colectomy on that admission.
Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment.
  • L. Benazzato, R. D'Incà, G. Sturniolo
  • Medicine
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2004
Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)
TLDR
The prognosis for UC during the first 10 years was generally good, the colectomy rate was low, and a large proportion of patients were in remission as time progressed, suggesting patients with initially extensive colitis and elevated ESR could benefit from an early potent medical treatment strategy.
Medical management of left‐sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials
TLDR
This critical evaluation of treatment provides a “report card“ on medications available for the management of patients with UP and L‐UC and should provide a useful reference and supplement for physicians treating UC patients.
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.
TLDR
At 1 year, 32% of patients with Crohn's disease and 48% with ulcerative colitis are corticosteroid free without operation.
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review
TLDR
The efficacy of azathioprine is reasonably well sustained over five years and there was no difference in relapse rates between Crohn's disease and ulcerative colitis.
Management of acute severe colitis.
TLDR
Decision-making is becoming more difficult with agents such as visilizumab, tacrolimus and the technique of leucocytapheresis as further options, Nevertheless, intravenous corticosteroids and timely colectomy have reduced mortality from nearly 30% to < 1% in specialist centres.
Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.
...
...